Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Exclusion Criteria

• •1. Contraindications for everolimus+exemestane treatment
• •2. Previous treatment with an anti-mTOR therapy
• •3. More than 1 previous line of chemotherapy in metastatic setting
• •4. Life expectancy \<3 months
• •5. Spinal cord compression and/or symptomatic or progressive brain metastases (unless asymptomatic or treated and stable off steroids for at least 30 days prior to start of study drug)
• •6. Haematopoietic function or organ impairment as shown by the following criteria:
• •* Polynuclear neutrophils \<1.5 x 10⁹/L
• •* Platelets \<100 x 10⁹/L
• •* Haemoglobin \<90 g/L
• •* Alanine aminotransferase (ALAT) / aspartate aminotransferase (ASAT) \>2.5 x ULN in the absence of or \>5 x upper limit of normal (ULN) in the presence of liver metastases
• •* Bilirubin \>1.5 x ULN
• •* Creatinine clearance ≤50 mL/min (measured or calculated by Cockcroft and Gault formula)
• •* Calcium and phosphate \>ULN
• •7. Abnormal coagulation or any other medical situation contraindicating biopsy
• •8. Bone metastases when this is the only site of biopsiable disease
• •9. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
• •10. Individuals deprived of liberty or placed under the authority of a tutor